(MedPage Today) — ORLANDO — The gene therapy exagamglogene autotemcel (exa-cel; Casgevy) — already approved for patients 12 years and older with transfusion-dependent beta-thalassemia (TDT) and sickle cell disease (SCD) — led to durable…
Source link : https://www.medpagetoday.com/meetingcoverage/ashhematology/118863
Author :
Publish date : 2025-12-06 12:00:00
Copyright for syndicated content belongs to the linked Source.
